

## FVC, FEV<sub>1</sub> and FEV<sub>1</sub>/FVC% in Type 2 Diabetes and Their Relationships with Duration of the Disease

Ali MO<sup>1</sup>, Begum S<sup>2</sup>, Begum N<sup>3</sup>, Ali T<sup>4</sup>, Ferdousi S<sup>5</sup>, Begum A<sup>6</sup>

### Abstract

**Background:** Diabetes mellitus is a chronic debilitating disease affecting various organs including lungs. The magnitude of the complications of this disease is related to its duration. **Objective:** To observe FVC, FEV<sub>1</sub> and FEV<sub>1</sub>/FVC% in type 2 diabetic patients and their relationship with duration of the disease. **Methods:** This cross-sectional study was carried out in the Department of Physiology, BSMMU, Dhaka, from July 2007 to June 2008 on 60 type 2 diabetic male patients of age 40-60 years (Group B). For comparison, 30 age and BMI matched apparently healthy non diabetic subjects (Group A) were also studied. Patients were selected from the out patient department of Bangladesh Institute of research on diabetes, endocrine and metabolic diseases. Based on duration of diabetes, diabetic patients were divided into B<sub>1</sub> (5-10 years) and B<sub>2</sub> (10-20 years). FVC, FEV<sub>1</sub> and FEV<sub>1</sub>/FVC% of all the subjects were measured by a digital microspirometer. Data were analyzed by One way ANOVA test, Unpaired Student's 't' test and Pearson's correlation coefficient test as applicable. **Results:** Mean of the percentage of the predicted values of FVC and FEV<sub>1</sub>, were significantly (p<0.001) lower in both those of Gr. B<sub>1</sub> and B<sub>2</sub> than that in A and were also significantly (p<0.001) lower in Gr. B<sub>2</sub> when compared with Gr. B<sub>1</sub>. Again, FEV<sub>1</sub>/FVC% was significantly (p<0.01) higher in Gr. B<sub>2</sub> than those in Gr. B<sub>1</sub> and A whereas this value was lower in Gr. B<sub>1</sub> than those of group A but it was not statistically significant. However, FVC and FEV<sub>1</sub> showed negative and FEV<sub>1</sub>/FVC% showed positive correlations with duration of diabetes. All these correlations were statistically non significant. **Conclusion:** From the result of this study it can be concluded that the ventilatory function of lung may be reduced in type 2 diabetes which may be related to the duration of the disease.

**Key words:** FVC, FEV<sub>1</sub>, diabetes mellitus

J Bangladesh Soc Physiol. 2009 Dec;4(2): 81-87

For author affiliations, see end of text.

<http://www.banglajol.info/index.php/JBSP>

### Introduction

The term diabetes mellitus describes a metabolic disorder of multiple aetiology characterized by chronic hyperglycemia with disturbances of carbohydrate, protein and fat metabolism resulting from defects in insulin secretion or insulin action or both<sup>1</sup>. It is a leading public health problem with increasing incidence and long term complications of various organs such as kidney, neuron, eye, heart etc. These complications are mainly a consequence of macro and micro vascular damages of the target organs<sup>2</sup>.

Like other target organs lung is also affected in diabetes<sup>3</sup>. Hyperglycemia causes micro vascular

changes such as thickening of basal lamina in the smaller vessels of the lungs, which causes reduction of its diffusing capacity of them. Hyperglycemia also causes some mechanical changes in the lungs. In this chronic disease, the susceptibility and severity of systemic inflammation increases which may cause peripheral airway obstruction<sup>4</sup> as well as fibrosis of lung tissue<sup>5</sup>. It was also observed that hyperglycemia affects the lung by non enzymatic glycation of chest wall and bronchial tree protein which prevents easy expansion<sup>6</sup>.

The duration of DM is an important factor affecting the lungs. Chronic hyperglycemia is

strongly associated with progressive neurogenic damage. Its severity and extent increases with the duration of diabetes. In 2000, Davis et al. observed that some pulmonary functions were decreased in type 2 diabetes and the reduction was directly proportionate to the duration of the disease<sup>6</sup>. In 2007, MEO et al. also observed that some spirometric lung function parameters were decreased in this group of patients and the decline was more in patients with longer duration of diabetes<sup>2</sup>.

The prevalence of diabetes is increasing day by day<sup>7</sup>. The number of diabetic patients in the world may be raised from 150 million to 220 million by the year 2010<sup>8</sup>. In our country, the number of diabetic patients is also increasing day by day. In 1966, about 1% people were affected by diabetes. But in 2003, it was about 15%<sup>9</sup>. It is surprising that there is no age limitation for presentation of type 2 diabetes. Many of the patients are diagnosed after development of one or more complications including nephropathy, neuropathy, retinopathy, and cardiovascular diseases. They also suffer from pulmonary complications.

Many studies on pulmonary functions in type 2 diabetic patients have been done in other countries. With the best of our knowledge no data is available in Bangladesh. Therefore, the present study was conducted to observe some aspects of lung functions in type 2 diabetic male to evaluate their lung function status and its association with duration of the disease.

### Methods

This cross-sectional study was carried out in the Department of Physiology, BSMMU, Dhaka, from July 2007 to June 2008 on 60 type 2 diabetic patients of 40-60 years old. For comparison, 30 age and BMI matched apparently healthy non diabetic subjects were (Group A) also studied. The patients were also matched with healthy subjects in terms of socioeconomic status. Based on duration of diabetes, diabetic patients were divided into B<sub>1</sub> (5-10 years) and B<sub>2</sub> (10-20 years).

The study group was selected from the Out Patients Department of BIRDEM. Subjects with history of COPD, asthma, smoking, heart disease, renal insufficiency, obesity, chest deformity and lung infections were excluded from the study. After selection of the subjects the purpose of the study was explained to each subject with a cordial attitude giving emphasis on the benefits they would obtain from this study. They were encouraged for voluntary participation. They were also allowed to withdraw themselves as soon as they need. To avoid the diurnal variation all the subjects were requested to attend at Department of Physiology BSMMU within 9 a.m. (after taking breakfast at 7 a.m) on the day of examination. Before examination an informed written consent was taken from each subject. A detail personal, medical, family, socio economic, occupational and drug history were recorded in a preformed questionnaire. Thorough physical examinations were done. Height and weight of the subjects were measured for calculation of BMI. 5 ml of venous blood was collected at 9 am from every patient for estimation of serum glucose, serum creatinine and HbA<sub>1c</sub> level in the blood as applicable. Then FVC, FEV<sub>1</sub>, FEV<sub>1</sub>/FVC% of all the subjects were measured by an electronic spirometer in the Respiratory Laboratory, Department of Physiology, BSMMU. Glycosylated hemoglobin (HbA<sub>1c</sub>) of diabetic patients was estimated by ion-exchange high-performance liquid chromatography (HPLC) method. Data were analyzed by One way ANOVA test, Unpaired Student's 't' test, and Pearson's correlation coefficient test as applicable.

### Results

The demographic variables of the study subjects are presented in Table-I. The groups were matched for age and BMI. Mean Glycosylated hemoglobin (HbA<sub>1c</sub>) levels in different duration of diabetes are shown in Figure 1. The mean ( $\pm$ SD) HbA<sub>1c</sub> level was significantly higher ( $p < 0.01$ ) in group B<sub>2</sub> when compared to B<sub>1</sub>.

**Table I:** Age and BMI in different groups (n=90)


Groups	n	Age (years)	BMI (kg/m <sup>2</sup> )
A	30	49.56 ± 5.59 (40 - 60)	20.63 ± 1.42 (18.5-22.9)
B <sub>1</sub>	30	51.70 ± 4.69 (42 - 60)	21.40 ± 1.70 (18.5 - 22.9)
B <sub>2</sub>	30	51.90 ± 5.82 (40 - 60)	21.30 ± 1.60 (18.5 - 22.9)

Statistical analysis:

Groups	p value	p value
A vs B <sub>1</sub> vs B <sub>2</sub>	0.184 <sup>ns</sup>	0.13 <sup>ns</sup>
A vs B <sub>1</sub>	0.115 <sup>ns</sup>	0.06 <sup>ns</sup>
A vs B <sub>2</sub>	0.119 <sup>ns</sup>	0.10 <sup>ns</sup>
B <sub>1</sub> vs B <sub>2</sub>	0.884 <sup>ns</sup>	0.80 <sup>ns</sup>

Data are expressed as Mean ± SD. For test of significance, one way ANOVA were performed for comparison among the groups. Independent 't' test was done to compare between the groups..

Group A = Apparently healthy non diabetic male for control.  
Group B<sub>1</sub> = Diabetic male with duration 5-10 years.  
Group B<sub>2</sub> = Diabetic male with duration 10-20 years.  
ns = Not significant. n = Number of subjects.



**Figure 1:** Mean Glycosylated Hb level in different duration of diabetes (n=60)

Group B<sub>1</sub> = Diabetic male with duration 5-10 years.  
Group B<sub>2</sub> = Diabetic male with duration 10-20 years.  
n = Number of subjects.

The results of FVC, FEV<sub>1</sub> and FEV<sub>1</sub>/FVC (%) are shown in Table II.

**Table II:** Mean percentage predicted values of FVC, FEV<sub>1</sub> and FEV<sub>1</sub>/FVC (%) in different groups (n=90)

Groups	n	FVC (litres)	FEV <sub>1</sub> (litres)	FEV <sub>1</sub> /FVC (%)
A	30	112.86 ± 11.97	130.13 ± 12.84	116.06 ± 6.31
B <sub>1</sub>	30	83.30 ± 7.69	101.30 ± 8.78	115.53 ± 6.77
B <sub>2</sub>	30	75.10 ± 8.95	85.51 ± 9.84	121.60 ± 6.78

Statistical analysis:

Groups	p value		
A vs B <sub>1</sub> vs B <sub>2</sub>	0.000***	0.000***	0.001***
A vs B <sub>1</sub>	0.000***	0.000***	0.753 <sup>ns</sup>
A vs B <sub>2</sub>	0.000***	0.000***	0.001***
B <sub>1</sub> vs B <sub>2</sub>	0.000***	0.000***	0.001***


Data are expressed as Mean ± SD. For test of significance, one way ANOVA were performed for comparison among the groups. Independent 't' test was done to compare between the groups.

Group A = Apparently healthy non diabetic male for control.  
Group B<sub>1</sub> = Diabetic male with duration 5-10 years.  
Group B<sub>2</sub> = Diabetic male with duration 10-20 years.  
\*\*\* = p < 0.001., ns = nonsignificant, n = Number of subjects.

The mean percentage of predicted values of FVC and FEV<sub>1</sub> in group B<sub>1</sub> and B<sub>2</sub> were significantly ( $p < 0.001$ ) lower than those of group A. Similarly, the values of FVC and FEV<sub>1</sub> in group B<sub>2</sub> were significantly ( $p < 0.001$ ) lower than B<sub>1</sub>. But the mean percentage of predicted values of FEV<sub>1</sub>/FVC (%) were significantly higher ( $p < 0.001$ ) in group B<sub>2</sub> compared to B<sub>1</sub>. No significant difference was found when this value was compared between group B<sub>1</sub> and group A.


Relationship of FVC, FEV<sub>1</sub> and FEV<sub>1</sub>/FVC (%) with duration of diabetes in the study groups were observed. The results are shown in Figure 2, 3 and 4.

FVC and FEV<sub>1</sub> were negatively and FEV<sub>1</sub>/FVC was positively correlated with duration of diabetes in both group B<sub>1</sub> and B<sub>2</sub>. But these relationships were not statistically significant.




**Figure 2:** Correlation of percentage predicted value of FVC with duration of diabetes in study groups (n=60)

Group B<sub>1</sub> = Diabetic male with duration 5-10 years  
Group B<sub>2</sub> = Diabetic male with duration 10-20 years



**Figure 3:** Correlation of percentage predicted values of FEV<sub>1</sub> with duration of diabetes in study Groups (n = 60)

Group B<sub>1</sub> = Diabetic male with duration 5-10 years  
Group B<sub>2</sub> = Diabetic male with duration 10-20 years



**Figure 4:** Correlation of percentage predicted value of FEV<sub>1</sub>/FVC (%) with duration of diabetes in study groups (n = 60).

Group B<sub>1</sub> = Diabetic male with duration 5-10 years  
Group B<sub>2</sub> = Diabetic male with duration 10-20 years  
HbA<sub>1c</sub> (%)

### Discussion

The present study was undertaken to observe some of the spirometric lung function variables in type 2 diabetic male subjects. Most of the values of lung function parameters in non diabetic subjects were within normal range and almost similar to the findings reported by different investigators of other countries<sup>10, 11</sup> as well as in our country<sup>12</sup>.

In this study, the mean of the percentage of predicted values of FVC and FEV<sub>1</sub> in type 2 diabetic patients of different duration were significantly lower than those of non diabetic subjects. These findings are consistent with findings of some investigators of different countries<sup>2, 3, 11</sup>. Again, these parameters in diabetic patients of 10-20 years duration was significantly lower when it was compared to that of 5-10 years duration of the disease. These findings are also in agreement with those of different investigators of other countries<sup>2, 6, 13</sup>.

FEV<sub>1</sub>/FVC (%) in the diabetic patients with 5-10 years duration was lower than that of the control group though the difference was not statistically significant. Sreeja et al. reported almost similar type of finding<sup>14</sup>. On the other hand, this parameter in the patients with 10-20 years of diabetes was significantly higher than those of the diabetic patients with 5-10 years duration and also the control group. However, almost similar type of finding was reported by different researchers although the differences were not statistically significant<sup>11</sup>.

The data of our study showed that FVC and FEV<sub>1</sub> were negatively but FEV<sub>1</sub>/FVC (%) was positively correlated with the duration of diabetes of both groups. All these relationships were statistically nonsignificant. These observations are in partial agreement with those of Meo et al. (2007). They found significant negative correlation with FVC and FEV<sub>1</sub><sup>2</sup>. On the other hand, Benbassat et al. observed no correlation between lung function parameters and duration of the disease or glycemic control subjects<sup>15</sup>.

Various studies suggested that diabetes mellitus may cause irreversible collagen cross linking in thoracic as well as lung tissue. In addition, chronic hyperglycemia causes fibrous tissue formation in the chest wall and bronchial tree protein (specially collagen) by non enzymatic glycation. This fibrous tissue may cause reduced compliance of lung and subsequent chronic airflow obstruction<sup>16</sup>. Long standing hyperglycemia may also cause autonomic as well as somatic (phrenic) neuropathy, which alters respiratory muscle function<sup>17</sup>.

Moreover, hyperglycemia causes over production of mitochondrial super oxides and ultimately a secondary reduction in antioxidant defense of the lungs. So there is increased susceptibility to environmental oxidative insults and subsequent loss of respiratory function<sup>18-19</sup>.

Diabetes mellitus is also associated with poor skeletal muscle strength due to increased protein catabolism<sup>20</sup>. For this reason respiratory muscle endurance also decreases in diabetes mellitus<sup>21</sup>.

In this study, comparatively reduced FVC and FEV<sub>1</sub> in diabetic patients of both group and its subnormal value in patients with longer duration denotes decreased lung compliance and air flow obstruction. Again, the increased ratio of FEV<sub>1</sub>/FVC (%) in diabetic patients of longer duration is due to disproportionate reduction of FVC and FEV<sub>1</sub>, which indicate that long-standing hyperglycemia may cause predominantly restrictive type of lung disorder. All these changes may be due to glycation of the chest wall and bronchial tree protein. This is further supported by negative correlation of FVC and FEV<sub>1</sub> and positive correlation of FEV<sub>1</sub>/FVC% with longer duration of diabetes. The negative correlation of FVC and FEV<sub>1</sub> with duration of diabetes indicate that long standing hyperglycemia may intensify the devastating effect of the disease.

### Conclusion

From this study it may be concluded that lung functions decreases in type 2 diabetic male and

the reduction is directly proportionate to the duration of the disease.

### Acknowledgement

The authors of this article are thankful to the authority of Bangladesh Institute of research on Diabetes, Endocrine and Metabolism (BIRDEM) for granting permission for sample collection.

### Author affiliations

- \*1. Md. Omar Ali, Assistant professor, Department of Physiology, Jahurul Islam Medical College. Email: omar ali dr@ gmail.com
2. Shelina Begum, Professor, Chairman, Department of Physiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh.
3. Noorzahan Begum, Professor & Chairman of the Department of Physiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh. Email: noorzahanbeg@ yahoo.com
4. Taskina Ali, Assistant Professor, Department of Physiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh. Email: taskinadr@ gmail.com
5. Sultana Ferdousi, Assistant Professor, Department of Physiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh. Email: sferdousiratna@ gmail.com
6. Afroza Begum Assistant Professor, (cc) Department of Community Medicine, Shahid Sohrwardy Medical college, Dhaka

\* For Correspondence

### References

1. WHO Definition Diagnosis and Classification of Diabetes Mellitus and its complications. Report of a WHO Consultation. Geneva. WHO; 1999.
2. Meo SA, Ahmed J, Shah SFA, Al-Regaiey K, Hussain A, Al-Rubean K. Effect of Duration of Disease on Ventilatory Function in an Ethnic Saudi Group of Diabetic Patients. *J Diabetes Sci Technol* 2007;1(5):711-717.
3. Davis WA, Knuiman M, Kendall P, Grange V, Davis TME. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes. *Diabetes Care*. 2004; 27:752-757).
4. Ford ES. Body Mass Index, Diabetes and C-Reactive Protein Among U. S. Adults. *Diabetes Care*. 1999; 22:1971-1977.
5. Weynand B, Jonckheere A, Frans A, Rahier J. Diabetes mellitus induces a thickening of pulmonary basal lamina. *Respiration*. 1999; 66(1): 14-19.
6. Davis TME, Knuiman M, Kendall P, Hien Vu, Davis WA. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study. *Diabet Research Clin Pract* 2000;50:153-159.
7. European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? *Br Med J*. 1998; 317: 371-375.
8. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. *Nature*. 2001; 414: 782-7.
9. Khan AKA, Mahtab H, Grant J, Stewart M, Ahmed T, Haq A. Diabetes mellitus. *Dibetic Association of Bangladesh*. 2005; 1(1): 21-22.
10. Sinha S, Guleria R, Mirsa A, Pandey RM, Yadav R, Tiwari S. Pulmonary functions in patients with type 2 diabetes mellitus. *Indian J Med Res* 2004; 119: 66-71.
11. Yen HC, Punjabi NM, Wang N, Pankow JS, Duncan BB, Brancati FL. Cross-Sectional and Prospective Study of Lung Function in Adults with Type 2 Diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. *Diabetes Care*. 2008; 31: 741-746.
12. Mostafa CGME. Effects of vitamins A, C and E on some aspects of lung function in smoker. (M. Phil. Thesis) [Dhaka(Bangladesh)]BSMMU; 2003. p86.
13. Bell D, Collier A, Matthews DM, Cooksey EJ, Mchardy GJ, Clarke BF. Are reduced lung volumes in IDDM due to defect in connective tissue? *Diabetes*. 1988; 37(6): 829-31.
14. Sreeja CK, Samuel E, Kesavachandran C, Shashidhar S. Pulmonary function in patients with diabetes mellitus. *Indian J Physiol Pharmacol*. 2003; 47(1):87-93.
15. Benbassat CA, Evin S, Mordechai K, Joseph L, Ilana B, Gershon MD. Pulmonary Function in Patients with Diabetes Mellitus. *Am J Med Sci*. 2001; 322(3): 127-132.
16. Schuyler MR, Niewoehner DE, Inkley SR, Kohn R. Abnormal lung elasticity in juvenile diabetes mellitus. *Am Rev Respir Dis*. 1976; 113(1): 37-41.
17. Villa MP, Cacciari E, Bernardi F, Cicognani A, Salardi S, Zapulla F. Bronchial reactivity in diabetic

- patients. Relationship to duration of diabetes and degree of glycemic control. *Arch Ped Adoles Med.* 1988; 142(7). 1708-1718.
18. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and pathogenesis of diabetic complications. *Ann Intern Med.* 1984; 101(4): 527-537.
  19. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications. *Clin Med.* 1986; 32(10 Suppl): B37-41.
  20. Park SW, Goodpaster BH, Strotmeyer ES, Rekeire N, Harris TB, Schwartz AN, Tylavsky FA, Newman AB. Decreased Muscle Strength and Quality in Older Adults With Type 2 Diabetes. The Health, Aging and Body Composition Study. *Diabetes* 2006; 55:1813-1818.
  21. Meo SA, Al-Drees AM, Arif M, Shah SFA, Al-Rubean K. Assessment of respiratory muscle endurance in diabetic patients. *Saudi Med J.* 2006; 27(2):223-6.